QualityDip
Get alerts
Prices as of Tue 5:00 pm ET

Stocks / Health Care · Medical Specialities

FRNM

Freenome Common stock FRNM

Health Care · Medical Specialities
$11.61−6.97% dayMon Nov 2 close

Outside our quality screen, so we don’t track its dips. It’s 32% below its 52-week high.

Outside our quality screen, 21% under its Market Value. No fair value estimate for now: there isn’t enough data.

Outside our quality screenReports Nov 10
Get alerts
Fair value est.
n/a
Market Value
$14.77price −21%
Off 52-wk high
−32%
Risk vs market
Lowbeta 0.66

52-week range 23% of the way from its 52-week low to its high

Low $9.99High $17.11

Price $11.61Market Value $14.77

1 bullish · 3 bearish See why

Covered for reference — doesn’t pass our quality screen (market cap $1.2B, under our $20B floor; no positive free cash flow; no return-on-capital data; debt load unclear or high). We show its price, Market Value and DCF, but it never appears in Dips, Top Picks or reversal signals. The screen

Valuation

What we estimate it's worth, and how it ranks on value vs every stock we cover.

Fair value estimate

No estimate for FRNM: Capital spending isn't tagged in SEC XBRL data. We’d rather show nothing than a made-up number.

Risk vs market

How risk vs market is measured

One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much FRNM moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.

Low

Moves much less than the market, but its own price swings are 3.8× the S&P 500’s (it moves on its own news).

Beta vs S&P 500
0.66
Volatility
49% vs 13% SPY
Correlation SPY
0.17
Correlation QQQ
0.19

Valuation details

MV $14.77

How

Market ValueAverage paid since the Aug 13 filing, 56 trading days
$14.77price −21%
Fair value estimaten/a — Capital spending isn't tagged in SEC XBRL data
n/a

Fundamentals

The business itself: sales, profits, cash and debt, from SEC filings.

Bull vs bear

Rule-based from the data on this page, strongest first. Not advice.

Top bullish points 1 of 5

  1. ValuationTrades 21.4% below its Market Value of $14.77, the average price paid since the Aug 13 filing.

Top bearish points 3 of 5

  1. ProfitabilityLost $762,626 over the last 12 months (net income, SEC filings).

  2. QualityDoesn’t pass our quality screen: no positive free cash flow; no return-on-capital data; debt load unclear or high.

  3. RiskReports earnings Nov 10: results can move the price sharply and reset Market Value.

All fundamentals

from SEC filings

Valuation

P/E
n/aloss over the last 12 months
Price / FCF
n/anot reported in its SEC filings
FCF yield
n/anot reported in its SEC filings
EV / EBITDA
n/aD&A or debt not tagged in SEC data
Price / sales
n/anot reported in its SEC filings
Price / book
n/anot reported in its SEC filings
Market cap
$1.2Blisted
Enterprise value
n/anot reported in its SEC filings

Growth

Revenue, 12 months
n/anot reported in its SEC filings
Sales growth, 12 months
n/ano year-ago 12-month revenue
Sales growth, 3 yrs
n/anot reported in its SEC filings
Diluted EPS, 12 months
n/anot reported in its SEC filings
EPS growth, last FY
n/afewer than two years of diluted EPS
Net income, 12 months
−$762,626
Net income growth
n/anot reported in its SEC filings

Profitability

Gross margin
n/agross profit isn't reported (common for service and financial companies)
Operating margin
n/anot reported in its SEC filings
Net margin
n/anot reported in its SEC filings
FCF margin
n/anot reported in its SEC filings
Return on equity
n/anegative shareholder equity
Return on invested capital
n/aoperating income, debt, equity or cash not tagged

Balance sheet

Cash & short-term inv.
$437,369
Total debt
n/anot reported in its SEC filings
Net cash
n/acash or debt not tagged in SEC data
Debt / equity
n/adebt or equity not tagged in SEC data
Interest coverage
n/ainterest expense not tagged in SEC data

Cash flow & returns

Free cash flow, 12 months
n/anot reported in its SEC filings
FCF growth, 12 months
n/anot reported in its SEC filings
Dividend yield
0%
Payout ratio
n/anot reported in its SEC filings
Buybacks, 12 months
n/anot reported in its SEC filings
Share count, 1 year
n/ano quarterly diluted share count
Stock-based comp
n/anot reported in its SEC filings

Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Freenome Common stock’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.

The business

Sales +106%
  • Gross margin0%
  • Operating marginn/m
  • Sales growth (latest quarter vs year-ago quarter)+106%

Chart & levels

Where the price is vs its key levels and trends.

$10$12$14$16Jan ’26AprJulOctMV $14.77
Market ValueDrag across the chart to see any day

Key levels

Every level vs today’s $11.61

  1. 52-wk lowlowest close, 1 year$9.99−14.0%
  2. PriceMon Nov 2 close$11.61you are here
  3. Market Valueavg paid since Aug 13$14.77+27.2%
  4. 52-wk highhighest close, 1 year$17.11+47.4%

Momentum & 52-week range

RSI 35 · 5 days −8.7%
$11.61nowMV
52-wk low $9.99high $17.11
Off 52-wk high−32.1%
5 days−8.7%
vs 50-day avg−21.0%
vs 200-day avg−7.2%
RSI (14), last close35
Market cap$1B

Signals

Reversal signal setups, the public ledger and the next earnings date.

Setup & signals

No setup armed

All setups

No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.

Next report

Nov 10

Calendar

  • DateTue Nov 10, after the close
  • Year-ago EPS$0.01
  • QuarterSep/2026

From Nasdaq’s earnings calendar. A report resets Market Value.

FRNM is outside our quality screen

One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.

By joining you agree we can text or email you about QualityDip. Message and data rates may apply. Reply STOP anytime. Not advice.

Voices & buzz

Who is talking about it, and how it compares with peers.

Who’s talking about it

Notable investors, executives, analysts and public figures on Freenome Common stock in the last 48 hours. Headlines as published, each linked. Their words, not ours.

No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.

Compare with peers

Closest in size in Medical Specialities

Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.